Navigation Links
Regado Biosciences, Inc. Announces Closing of Initial Public Offering
Date:8/27/2013

BASKING RIDGE, N.J., Aug. 27, 2013 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), today announced the closing of its previously announced initial public offering of 10,750,000 shares of common stock, at a public offering price of $4.00 per share, resulting in gross proceeds of $43,000,000, before deducting the underwriting discounts and commissions and other offering expenses payable by Regado Biosciences.  All of the common stock was offered by Regado Biosciences.  The company's common stock is listed on The NASDAQ Capital Market under the trading symbol "RGDO."

Cowen and Company, LLC and BMO Capital Markets Corp. acted as joint book-running managers for the offering.  Canaccord Genuity Inc., Needham & Company, LLC, and Wedbush PacGrow Life Sciences acted as co-managers. 

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on August 21, 2013.  This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering will be made only by means of a prospectus.  Copies of the final prospectus related to the offering may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,11717, Attn: Prospectus Department, Phone (631) 274-2806 / Fax (631) 254-7140; or from BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, Telephone: (800) 414-3627, Email: bmoprospectus@bmo.c
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
2. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
3. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
4. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
5. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
6. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
7. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
8. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
9. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
10. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
11. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014   Regulus Therapeutics Inc ... company leading the discovery and development of innovative ... its ATHENA natural history of disease study in ... disease with no approved therapy. The ATHENA study ... renal function markers such as Glomerular Filtration Rate ...
(Date:9/18/2014)... and ROCKVILLE, Md. , ... SPPI ), a biotechnology company with fully integrated ... in hematology and oncology, and CASI Pharmaceuticals, Inc. (Nasdaq: ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a primary focus on China ...
(Date:9/18/2014)... Sept. 18, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that the Company,s ... Geert Cauwenbergh , will present at the ... on Wednesday, September 24, 2014 at 11:20 ...
Breaking Medicine Technology:Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 2Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 3Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 4Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 5Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 6Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 7Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 8Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 9Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs 10RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 2RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference 3
... 2011 On Sunday, August 21, veterinary cardiologists are ... the Mobile Dog Heart Health Tour will stop with ... examinations at Peters Park Dog Run. (Photo: ... free heart health screenings, veterinarians will be available to ...
... Unilife Corporation ("Unilife" or the "Company") (NASDAQ: ... it has finalized a previously disclosed Equipment Financing ... $10 million in available funding. This agreement will ... finance the automated assembly line now manufacturing the ...
Cached Medicine Technology:Free Dog Heart Health Screenings Available August 21 in Boston 2Unilife Signs $10 Million Equipment Financing Agreement 2Unilife Signs $10 Million Equipment Financing Agreement 3Unilife Signs $10 Million Equipment Financing Agreement 4
(Date:9/18/2014)... Qualis Health, one of the nation’s leading population ... “Advancing Primary Care through the Patient-Centered Medical Home Model ... Jeff Hummel, MD, MPH and Peggy C. Evans, PhD, ... the work of becoming a Patient-Centered Medical Home (PCMH) ... such as generating and providing useful data that can ...
(Date:9/18/2014)... developed a new method to study Ebola virus in ... Conservation Society (WCS)-led research, published today in the journal ... of fecal samples from wild great apes to identify ... This represents a new tool for performing large, population-scale ... virus is studied and improve our understanding of the ...
(Date:9/18/2014)... recommending that elderly men should not be routinely screened ... to a new study led by researchers at Henry ... online in JAMA Internal Medicine , focused on ... test for prostate cancer., "We found that the effect ... elderly men in particular has been minimal at best," ...
(Date:9/18/2014)... 2014 With the swift industrial development ... such as smart phones, tablets and PDAs, a complete ... mobile devices are viewed these days. From only being ... becoming a mode for creating and delivering content while ... way. , The complete makeover of this ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 A sold-out ... community advocates, and volunteers supported United Way of ... Chefs and Fine Wines” event Monday, Sept. 15. Proceeds ... health initiatives in Westchester and Putnam, such as providing ... steering teens away from risky behaviors like drug and ...
Breaking Medicine News(10 mins):Health News:Advancing Primary Care Through PCMH and HIT: New White Paper Connects the Dots 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:Professional recommendations against routine prostate cancer screening have little effect 2Health News:Transparency Market Research: M-health Market Study 2018 2Health News:Transparency Market Research: M-health Market Study 2018 3Health News:Transparency Market Research: M-health Market Study 2018 4Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 2Health News:United Way Celebrates “Best Chefs and Fine Wines” at Sold-Out Culinary Event 3
... people who have optic nerve damage might be at ... the study researchers involved 25 people with visual impairment. ... days, and their results were compared with those of ... that those with optic nerve disease were 20-times more ...
... inflammation of the liver and can cause complications such ... the hepatitis B vaccine is recommended for infants. Previous ... against infection for up to 10 years. However, a ... 10 years. ,Researchers followed eight-hundred-and-forty-one Alaska natives vaccinated ...
... of the expectant mother. Now a new study suggests ... of preeclampsia in the pregnant women. ,The ... with periodontitis with atherosclerosis to preeclampsia. Such an oral ... abuse like smoking, etc. The basic reason for setting ...
... and vitamin B12 are safe and effective in reducing the ... a stroke . According to researchers stroke patients have a ... healthy peers due to higher levels of plasma homocysteine in ... of hip fracture. ,The study was initiated to ...
... in Japan, even after the country has banned the shots of ... of the must-have vaccines to be given to children before they ... journal Lancet in 1998 had published a paper relating the MMR ... there had been considerable fall in vaccinating children with MMR (Measles, ...
... benefits of alcohol consumption and cardiovascular disease researchers studied ... // moderate levels of alcohol (one to seven drinks ... eight drinks per week), and did not consume any ... first to focus on the association between alcohol intake ...
Cached Medicine News:
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Curette, 145 mm...
Bone Currettes...
Medicine Products: